10x Genomics, Inc.
A life-sciences technology company that makes instruments, consumables, and software for studying biology at the level of individual cells and their spatial context, using its Chromium and Visium platforms. Founded in 2012 in Pleasanton, California, by Serge Saxonov, Ben Hindson, and Kevin Ness, the company's name reflects their goal of a ten-fold, or "10x," improvement in biological resolution rather than incremental progress.
Granted 545.1K · Sold 219.5K
Granted 288.8K · Sold 81.4K
Granted 32.8K
Granted 442.2K · Sold 79.5K
Granted 8.6K
Granted 53.3K · Sold 9.4K
Granted 45.9K · Bought 40.0K
Sold 18.2K
Granted 32.8K
Granted 32.8K
Granted 43.2K · Sold 7.6K
Granted 32.8K · Sold 7.9K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Saxonov SergeChief Executive Officer, Director · 54 transactions | — | 4.40M | 545.1K | — | 219.5K |
| Hindson Benjamin J.See Remarks, Director · 16 transactions | +73.9% | 488.2K | 288.8K | — | 81.4K |
| Stuelpnagel John RDirector · 3 transactions | +9.8% | 368.4K | 32.8K | — | — |
| Taich AdamChief Financial Officer · 9 transactions | — | 362.7K | 442.2K | — | 79.5K |
| Mammen MathaiDirector · 1 transaction | +5% | 180.3Kas of Jun 2024 | 8.6K | — | — |
| McAnear Justin J.Former Chief Financial Officer · 5 transactions | +45% | 143.2Kas of Aug 2024 | 53.3K | — | 9.4K |
| Mateo AlanDirector · 4 transactions | — | 85.9K | 45.9K | 40.0K | — |
| Wilbur JamesChief Commercial Officer · 2 transactions | -17.7% | 83.3Kas of Nov 2023 | — | — | 18.2K |
| Kosaraju SridharDirector · 3 transactions | +92.6% | 68.3K | 32.8K | — | — |
| Popovits Kimberly JDirector · 3 transactions | +712.3% | 37.4K | 32.8K | — | — |
| Teichmann Sarah A.Director · 4 transactions | — | 35.6K | 43.2K | — | 7.6K |
| Suliman ShehnaazDirector · 7 transactions | +540.2% | 29.5K | 32.8K | — | 7.9K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 3 years: -383.5K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.